Compare Marathon Petroleum Corp (MPC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs TG Therapeutics Inc — how do they compare? Marathon Petroleum Corp trades at $401.83 (market cap $111.70B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Marathon Petroleum Corp is far larger — about 13.1× TG Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 1.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPC | TGTX | |
|---|---|---|
Market Cap | $111.70B | $8.53B |
Sector | Energy | Health |
52-Week High | $399.44 | $59.06 |
52-Week Low | $162.63 | $26.94 |
Enterprise Value | $138.23B | $8.74B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today, and is near its 52-week high. The stock shows strong momentum with bullish technical signals and has consistently beaten earnings estimates in recent quarters. Key fundamentals include a P/E of 13.79, robust ROE of 47.9%, and positive cash flow trends. Recent news highlights refinery efficiency gains and geopolitical tailwinds boosting energy sector sentiment.
Outlook remains positive given strong analyst consensus (78.79% buy ratings) and projected revenue growth to $153.6B in 2026. Risks include cyclical energy demand volatility and rising debt-to-asset ratios. The stock offers value through earnings momentum but faces headwinds from macroeconomic uncertainty.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
